A new phase 3 hormone-regimen strategy around surgery showed signals of improved outcomes in high-risk early prostate cancer at ASCO. J&J’s Erleada (apalutamide) reduced the risk of metastasis or death by 20% when used as part of a hormone therapy schedule given around surgery, according to data reported at the meeting. Separately, STAT described a broader debate among oncologists about how to interpret survival and clinical adoption implications when multiple endocrine combinations are being tested in similar surgical pathways. The ASCO discussions highlighted that while the direction of effect is favorable, questions remain about which patient groups and regimen components should drive standard-of-care changes.